Mereo BioPharma Group plc (MREO) - Not Halal (Non-Compliant)
Mereo BioPharma Group plc (MREO) is classified as Not Halal (Non-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
- Sector
- Healthcare
- Industry
- Biotechnology
- Result
- Pass
- Reason
- The sector "Healthcare" and industry "Biotechnology" are not in the excluded categories.
Financial Ratios
- Debt Ratio
- Value: 1.5% | Threshold: 30% | Result: Pass
- Cash & Interest-bearing Securities Ratio
- Value: 45.2% | Threshold: 30% | Result: Fail
- Non-Permissible Income Ratio
- Value: 434.6% | Threshold: 5% | Result: Fail
Dividend Purification
Purification percentage: 100.00%.Based on the company's financial statements, approximately 100.00% of dividend income should be donated to charity for purification. This is derived from identified interest income (434.60% of total income). Some scholars may differ on the exact calculation method.
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.